https://www.triatomic.capital/portfolio daily 0.75 2024-08-10 https://www.triatomic.capital/home daily 1.0 2023-02-28 https://www.triatomic.capital/team daily 0.75 2023-03-01 https://images.squarespace-cdn.com/content/v1/61da8045b1f95a562b0cb218/ac103a8a-cb83-4ed9-8c28-b74589287319/sh-round.png Team - Steve Hochberg Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/61da8045b1f95a562b0cb218/15c19be3-809e-4dbf-b9db-712dbf15793c/jhuber-round.png Team - Jeff Huber Jeff Huber is the Founding CEO of GRAIL. GRAIL's mission is to detect cancer early, when it can be cured. Jeff is also the Co-Founder & President of OpenCovidScreen (2020-present), a non-profit focused on catalyzing innovation in COVID-19 testing/screening that is Frequent, Fast-turnaround, Cheap, and Easy ("FFCE"). Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google's life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development. Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology companies, including Openwater, Mammoth Biosciences, LytEn, Vir, Sana, Atomwise, Genalyte, Synthego, Apexigen, Tachyon Therapeutics, Mirvie, Pinterest, Honor, OpenDoor, Bolt, and AngelList. Jeff holds a bachelor's degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a 'Distinguished Alumni Award' from the College of Electrical & Computer Engineering (2018) for 'challenging the status quo through innovation'. He also holds a master's degree in business from Harvard University, and was a Visiting Scholar in Stanford University's Department of BioEngineering (2017-2020). Jeff is a board member of Mammoth Biosciences, Electronic Arts (EA), Upstart (UPST), Openwater, Genalyte (Chairman), Zapata Computing, and the Parker Institute for Cancer Immunotherapy (PICI), and is a former board member of GRAIL (2016-2021; acquired for $10.1B), Aldevron (2019-2021; acquired for $9.6B), Ancestry.com (2018-2020; acquired for $4.7B), Weta Digital (2020-2021; tech assets acquired for $1.625B), and Illumina (ILMN; 2014-2016). Jeff is an advisory board member for Stanford's Precision Health and Integrated Diagnostics Center (PHIND), Duke University's Research Translation & Commercialization (RTC) Council, and sponsors the 'Huber-Vossough Chancellor’s Chair' in Computational Biomedicine at UC Berkeley. https://images.squarespace-cdn.com/content/v1/61da8045b1f95a562b0cb218/f888fb01-3329-47cf-b370-ca6f06555883/pz-round.png Team - Peter Zhou Peter Zhou is founder and portfolio manager at Hongkou Capital, a fundamental long/short hybrid equity fund which will be a part of Triatomic. Since founding Hongkou in 2021, Peter has invested in several early and late stage companies across health tech, deep tech, and AI. Between 2010 and 2020, Peter was a Senior Managing Director at Coatue Management where he managed investments across tech, healthcare, consumer, and other sectors. Previously, Peter was a private equity analyst at Blackstone, where he worked on transactions in New York, Hong Kong, and Beijing. Peter sits on the Board of Trustees of the Cancer Research Institute, one of the first backers of cancer immunotherapy research. Peter also serves on the Board of Directors of the Park Avenue Armory. Peter graduated from Harvard University in 2007 with a degree in Economics. https://www.triatomic.capital/about daily 0.75 2023-03-01 https://images.squarespace-cdn.com/content/v1/61da8045b1f95a562b0cb218/b6c1b128-6fc2-413e-8759-b06d8a71b2d9/Artificial-Intelligence-in-the-Biotechnology-bnr.jpg About - Investing and helping build ‘century defining’ technologies and businesses. Engineered biology – cell & gene therapies, AI-driven discovery, synthetic biology, multiomic & protein sequencing, early detection New energy – battery tech/storage, fusion, next-gen nuclear Next gen compute – AI processors, next-gen compute architecture, sensors, scalable quantum computing & optimization, data-science platforms Automated economy – smart contracts, blockchain/crypto infrastructure, digital rights, software-enabled services, robotics, security Engineered materials – deterministic material design & manufacturing, computational chemistry, nanomaterials https://www.triatomic.capital/privacy-policy daily 0.75 2023-03-01